title: Basiliximab interferes with the detection of soluble IL-2 receptor by the Immulite Immunoassay system.
abstract: The use of the Immulite Automated Immunoassay system is becoming an increasingly popular method for accurate and fast measurement of sIL-2R in serum. Here, we report that detection of sIL-2R using the Immulite Immunoassay system in serum samples of patients who are treated with basiliximab, a monoclonal antibody against the alpha-chain of the IL-2 receptor, may lead to false measurements.
authors.affiliation: Department of Surgery, Erasmus Medical Center Rotterdam, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
authors.forename: Michiel C
authors.initials: MC
authors.lastname: Warlé
authors.forename: Jaap
authors.initials: J
authors.lastname: Kwekkeboom
authors.forename: Hugo W
authors.initials: HW
authors.lastname: Tilanus
authors.forename: Herold J
authors.initials: HJ
authors.lastname: Metselaar
mesh_terms: D000911:Antibodies, Monoclonal / Q000097:blood* / Q000627:therapeutic use; D000077552:Basiliximab; D001667:Binding, Competitive; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D007166:Immunosuppressive Agents / Q000097:blood / Q000627:therapeutic use; D016031:Liver Transplantation / Q000276:immunology; D015375:Receptors, Interleukin-2 / Q000097:blood*; D011993:Recombinant Fusion Proteins; D012995:Solubility; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab